A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

The aim of this phase II trial was to estimate the objective response rate (ORR) of two different schedules of ixabepilone [weekly or every 3 weeks (Q3W)] combined with bevacizumab, relative to a reference arm of weekly paclitaxel and bevacizumab. Patients with human epidermal growth factor receptor...

詳細記述

保存先:
書誌詳細
主要な著者: Rugo, Hope S., Campone, Mario, Amadori, Dino, Aldrighetti, Daniela, Conte, PierFranco, Wardley, Andrew, Villanueva, Cristian, Melisko, Michelle, McHenry, M. Brent, Liu, David, Lee, Francis, Pivot, Xavier
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2013
主題:
Clinical Trial
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3669514/
https://ncbi.nlm.nih.gov/pubmed/23649189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2552-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料